IN8bio’s Strategic Growth and Development: Buy Rating Affirmed by Soumit Roy

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on IN8bio (INAB – Research Report), with a price target of $1.20.

Soumit Roy has given his Buy rating due to a combination of factors that highlight the potential growth and development opportunities for IN8bio. The company is advancing multiple assets, with a particular focus on their CD19 targeting γδ TCE, known as INB-619. This asset is expected to show promising preclinical data, particularly in its cytotoxicity profile, which will be presented at the ASGCT conference.
Additionally, IN8bio is preparing to present further data on their INB-200 asset in glioblastoma, which could open up new business development opportunities. The company’s ongoing leukemia program, with an anticipated data update in the second half of 2025, also contributes to the positive outlook. Furthermore, management’s exploration of partnerships and collaborations for the INB-600 platform in oncology and autoimmune indications underscores the strategic initiatives that support the Buy rating.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $6.00 price target.